Insiders Trades
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (17 ops.)
Latest filing published 06 Oct 2026 for Mirum Pharmaceuticals, Inc., €91k. Read the official filing
Filing timeline
BuySaleChristopher Peetz
Insider track record
Disclosed buys
2
Disclosed sells
17
Signal history
Closed purchases
Market purchases
2
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- +31.1%Entry US$14.23 · Close at T+365 US$18.65
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Christopher Peetz: trading record in brief
Christopher Peetz (chief executive) discloses dealings in 3 companies, chiefly Mirum Pharmaceuticals, Inc., Alpine Immune Sciences, Inc. and Arcutis Biotherapeutics, Inc. Over a trading history stretching from 10 May 2021 to 6 October 2026, the count stands at 46 filings.
In open-market terms, that means 2 purchases worth €106k on one side and 17 sales worth €8.5M on the other. On balance, insiders were net sellers of €8.3M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 10 share grants and 15 option exercises. 2026 to date brings no purchases and 10 sales.
Most recently, on 6 October 2026, the filings show an option exercise worth €91k in Mirum Pharmaceuticals, Inc. The latest purchase dates back some time: it was published 1,784 days ago, on 29 November 2021. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Christopher Peetz
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations46 total
5,305 shares@ US$19.19Common StockSEC:0001614740-26-000014:0
6,892 shares@ US$15.87Common StockSEC:0001614740-26-000014:1
30,000 shares@ US$2.9360.0015% mcap0.8% of flowCommon StockSEC:0001614740-26-000013:0
8,312 shares@ US$98.080.014% mcap7.5% of flowCommon StockSEC:0001614740-26-000013:1
21,688 shares@ US$98.910.036% mcap19.6% of flowCommon StockSEC:0001614740-26-000013:2
20,000 shares@ US$2.9360.0010% mcap0.5% of flowCommon StockSEC:0001614740-26-000012:0
11,683 shares@ US$98.510.019% mcap10.6% of flowCommon StockSEC:0001614740-26-000012:1
6,017 shares@ US$99.250.010% mcap5.5% of flowCommon StockSEC:0001614740-26-000012:2
2,300 shares@ US$100.140.0039% mcap2.1% of flowCommon StockSEC:0001614740-26-000012:3
4,315 shares0Common StockSEC:0001628280-26-048655:0
20,000 shares@ US$2.9360.0010% mcap0.5% of flowCommon StockSEC:0001614740-26-000011:0
12,134 shares@ US$121.650.025% mcap13.7% of flowCommon StockSEC:0001614740-26-000011:1
4,181 shares@ US$122.340.0087% mcap4.8% of flowCommon StockSEC:0001614740-26-000011:2
1,975 shares@ US$123.740.0042% mcap2.3% of flowCommon StockSEC:0001614740-26-000011:3
1,710 shares@ US$124.790.0036% mcap2.0% of flowCommon StockSEC:0001614740-26-000011:4
25,000 sharesCommon StockSEC:0001614740-26-000009:0
9,108 shares@ US$103.30358.4% of flowCommon StockSEC:0001614740-26-000007:0
12,500 sharesCommon StockSEC:0001614740-26-000003:0
12,797 sharesCommon StockSEC:0001614740-26-000002:0
21,070 shares0Common StockSEC:0001614740-26-000001:0
19,133 shares@ US$19.243.4% of flowCommon StockSEC:0001614740-25-000005:0
40,000 shares@ US$2.9361.1% of flowCommon StockSEC:0001415889-25-021521:0
40,000 shares@ US$2.9361.1% of flowCommon StockSEC:0001415889-25-021350:0
50,000 sharesCommon StockSEC:0001415889-25-008556:0
40,000 shares@ US$2.9361.2% of flowCommon StockSEC:0001415889-25-006524:0
25 of 46 declarations
